Effect of periodontal inflammatory on SARS-CoV-2 receptor expressio
Recruiting
- Conditions
- Periodontitis stage II to IV, grade A to C
- Registration Number
- DRKS00026710
- Lead Sponsor
- Deutsche Gesellschaft für Parodontologie e. V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
10 own teeth
Periodontitis patients: stage II to IV, grade A to C;
Controls: no attachment loss detectable, probing depths (exclusion of pseudo-pockets) = 3 mm, bleeding on probing < 10%.
Exclusion Criteria
Systemic antibiotic therapy and subgingival periodontal therapy in the last 6 months; pregnancy; general diseases with known association to periodontitis, (e.g. diabetes mellitus type I/II, coronary heart disease), medication leading to hyperplasia.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of SARS-CoV-2 receptor expression; ACE2, DPP4/CD26, CD39, CD73, and APN/CD13.
- Secondary Outcome Measures
Name Time Method Genotyping of the SARS-CoV-2 receptors.<br>ACE2, DPP4/CD26, CD39, CD73, and APN/CD13.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does periodontal inflammation affect SARS-CoV-2 receptor (ACE2) expression mechanisms?
Are specific cytokines in periodontitis stages II-IV correlated with ACE2 upregulation?
What biomarkers in DRKS00026710 predict altered SARS-CoV-2 receptor dynamics in periodontitis?
Could periodontal treatment strategies reduce ACE2 levels and SARS-CoV-2 susceptibility?
How do ParCov trial findings compare to other studies on ACE2 modulation by oral inflammation?